BD Life Sciences-Diagnostic Systems has launched BD SurePath Direct to Slide, a liquid based Cytology (LBC) test.
The diagnostic test is intended to be used for screening and detection of cervical cancer, precancerous lesions, atypical cells and all other cytologic categories.
BD SurePath Direct to Slide is an LBC technique that will offer availability of residual sample for conducting important additional follow up tests without the need for repeat sampling.
“Women undergoing screening should opt for liquid based cytology as a the screening test since it has demonstrated the ability to detect abnormal cells at the initial stages of pre–cancer, thus, preventing cervical cancer from progressing, and ensuring cure when detected and treated early enough,” said Dr Minaxi Desai–Ex-Director, Manchester Cytology Centre, Manchester Royal Infirmary, UK.
LBC also offers the advantage of higher accuracy, shorter screening time and subsequent molecular studies on the same sample.